	US 12,454,577 B2
	Trimeric polypeptide complexes comprising a collagen XVIII homotrimerization domain and/or a collagen xv homotrimerization and an agonist of a TNFR family costimulatory receptor, encoding polynucleotide thereof and method of use thereof to treat cancer
Marta Compte Grau, Madrid (ES); and Luis Álvarez Vallina, Madrid (ES)
Assigned to LEADARTIS, S.L., Madrid (ES)
Appl. No. 16/972,654
Filed by LEADARTIS, S.L., Madrid (ES)
PCT Filed Jun. 6, 2019, PCT No. PCT/EP2019/064864 § 371(c)(1), (2) Date Dec. 7, 2020, PCT Pub. No. WO2019/234187, PCT Pub. Date Dec. 12, 2019.
Claims priority of application No. 18382401 (EP), filed on Jun. 6, 2018.
Prior Publication US 2021/0246217 A1, Aug. 12, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01)

CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); C07K 16/2863 (2013.01); C07K 16/3007 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

27 Claims

1. A trimeric polypeptide complex comprising three monomer polypeptides

wherein each monomer polypeptide comprises:

i. a homotrimerization domain selected from the group consisting of the collagen XVIII homotrimerization domain (TIE^XVIII), the collagen XV homotrimerization domain (TIE^XV) and a functionally equivalent variant thereof, wherein the functionally equivalent variant of TIE^XVIIIis a sequence showing at least 80% identity with the sequence SEQ ID NO: 12 and the functionally equivalent variant of TIE^XVis a sequence showing at least 80% identity with the sequence SEQ ID NO: 2; and

ii. an agonist of a TNFR family costimulatory receptor, and

wherein at least one monomer polypeptide further comprises a polypeptide region which is capable of specifically binding to a tumor associated antigen.